BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Y, Liang Y, Sang Y, Song X, Zhang H, Liu Y, Jiang L, Yang Q. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis 2018;9:14. [PMID: 29323124 DOI: 10.1038/s41419-017-0030-7] [Cited by in Crossref: 78] [Cited by in F6Publishing: 87] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Meng Q, Deng Y, lu Y, Wu C, Tang S. Tumor-derived miRNAs as tumor microenvironment regulators for synergistic therapeutic options. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04432-0] [Reference Citation Analysis]
2 Nasrolahi A, Azizidoost S, Radoszkiewicz K, Najafi S, Ghaedrahmati F, Sheykhi-sabzehpoush M, Poodineh J, Hajizadeh M, Anbiyaiee A, Farzaneh M, Feghhi M. Long non-coding RNAs involved in retinoblastoma. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04398-z] [Reference Citation Analysis]
3 Yi X, Huang D, Li Z, Wang X, Yang T, Zhao M, Wu J, Zhong T. The role and application of small extracellular vesicles in breast cancer. Front Oncol 2022;12:980404. [DOI: 10.3389/fonc.2022.980404] [Reference Citation Analysis]
4 Meng L, Song K, Li S, Kang Y. Exosomes: Small Vesicles with Important Roles in the Development, Metastasis and Treatment of Breast Cancer. Membranes 2022;12:775. [DOI: 10.3390/membranes12080775] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Li Y, Meng L, Li B, Li Y, Shen T, Zhao B, Wu X. The Exosome Journey: From Biogenesis to Regulation and Function in Cancers. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/9356807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhao J, Guo J, Wang Y, Ma Q, Shi Y, Cheng F, Lu Q, Fu W, Ouyang G, Zhang J, Xu Q, Hu X. Research Progress of DUB Enzyme in Hepatocellular Carcinoma. Front Oncol 2022;12:920287. [DOI: 10.3389/fonc.2022.920287] [Reference Citation Analysis]
7 Si Z, Zhong Y, Lao S, Wu Y, Zhong G, Zeng W. The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review. Front Oncol 2022;12:899145. [PMID: 35664800 DOI: 10.3389/fonc.2022.899145] [Reference Citation Analysis]
8 Zhu Y, Li F, Wan Y, Liang H, Li S, Peng B, Shao L, Xu Y, Jiang D. Cancer-Secreted Exosomal MiR-620 Inhibits ESCC Aerobic Glycolysis via FOXM1/HER2 Pathway and Promotes Metastasis. Front Oncol 2022;12:756109. [DOI: 10.3389/fonc.2022.756109] [Reference Citation Analysis]
9 Bai S, Wang Z, Wang M, Li J, Wei Y, Xu R, Du J. Tumor-Derived Exosomes Modulate Primary Site Tumor Metastasis. Front Cell Dev Biol 2022;10:752818. [PMID: 35309949 DOI: 10.3389/fcell.2022.752818] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dong M, Liu Q, Xu Y, Zhang Q. Extracellular Vesicles: The Landscape in the Progression, Diagnosis, and Treatment of Triple-Negative Breast Cancer. Front Cell Dev Biol 2022;10:842898. [PMID: 35300426 DOI: 10.3389/fcell.2022.842898] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
11 Wu L, Tian K, Ding Z, Zhao T, Zhang X, Cheng W, Gao S, Lu Q, Kaplan DL. MSC‐Laden Composite Hydrogels for Inflammation and Angiogenic Regulation for Skin Flap Repair. Advanced Therapeutics. [DOI: 10.1002/adtp.202100231] [Reference Citation Analysis]
12 Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Int J Mol Sci 2022;23:1665. [PMID: 35163586 DOI: 10.3390/ijms23031665] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
13 St-Denis-Bissonnette F, Khoury R, Mediratta K, El-Sahli S, Wang L, Lavoie JR. Applications of Extracellular Vesicles in Triple-Negative Breast Cancer. Cancers (Basel) 2022;14:451. [PMID: 35053616 DOI: 10.3390/cancers14020451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Li J, Quan X, Lei S, Chen G, Hong J, Huang Z, Wang Q, Song W, Yang X. LncRNA MEG3 alleviates PFOS induced placental cell growth inhibition through its derived miR-770 targeting PTX3. Environ Pollut 2022;293:118542. [PMID: 34801623 DOI: 10.1016/j.envpol.2021.118542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zeng X, Ma X, Guo H, Wei L, Zhang Y, Sun C, Han N, Sun S, Zhang N. MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8. Bioengineered 2021;12:10126-35. [PMID: 34978519 DOI: 10.1080/21655979.2021.2000741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Jain V, Kumar H, Jain R. Targeting triple-negative breast cancers using nanomedicine. Targeted Nanomedicine for Breast Cancer Therapy 2022. [DOI: 10.1016/b978-0-12-824476-0.00004-8] [Reference Citation Analysis]
17 Sharkas S, Song M, Chomchan P, Rossi J. MicroRNAs and cancer. MicroRNA 2022. [DOI: 10.1016/b978-0-323-89774-7.00016-9] [Reference Citation Analysis]
18 Xia M, Zu X, Chen Z, Wen G, Zhong J. Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance. Cancer Lett 2021;523:100-10. [PMID: 34601022 DOI: 10.1016/j.canlet.2021.09.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Tang W, Xia M, Liao Y, Fang Y, Wen G, Zhong J. Exosomes in triple negative breast cancer: From bench to bedside. Cancer Lett 2021;527:1-9. [PMID: 34902521 DOI: 10.1016/j.canlet.2021.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Jain N, Das B, Mallick B. miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug efflux. DNA Repair (Amst) 2021;109:103259. [PMID: 34871862 DOI: 10.1016/j.dnarep.2021.103259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Chen W, Li Z, Deng P, Li Z, Xu Y, Li H, Su W, Qin J. Advances of Exosomal miRNAs in Breast Cancer Progression and Diagnosis. Diagnostics (Basel) 2021;11:2151. [PMID: 34829498 DOI: 10.3390/diagnostics11112151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Wang X, Sun C, Huang X, Li J, Fu Z, Li W, Yin Y. The Advancing Roles of Exosomes in Breast Cancer. Front Cell Dev Biol 2021;9:731062. [PMID: 34790660 DOI: 10.3389/fcell.2021.731062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
23 Yi Y, Wu M, Zeng H, Hu W, Zhao C, Xiong M, Lv W, Deng P, Zhang Q, Wu Y. Tumor-Derived Exosomal Non-Coding RNAs: The Emerging Mechanisms and Potential Clinical Applications in Breast Cancer. Front Oncol 2021;11:738945. [PMID: 34707990 DOI: 10.3389/fonc.2021.738945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
24 Zhong Y, Li H, Li P, Chen Y, Zhang M, Yuan Z, Zhang Y, Xu Z, Luo G, Fang Y, Li X. Exosomes: A New Pathway for Cancer Drug Resistance. Front Oncol 2021;11:743556. [PMID: 34631581 DOI: 10.3389/fonc.2021.743556] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
25 Arumugam P, Sampathkumar B, Perumalsamy H, Balusamy SR, Ramesh V, Sundaravadevel S. Synergistic effect of anethole and doxorubicin alleviates cell proliferation, cell cycle arrest, and ER stress and promotes ROS-mediated apoptosis in triple-negative breast cancer cells. J Biochem Mol Toxicol 2021;:e22928. [PMID: 34585488 DOI: 10.1002/jbt.22928] [Reference Citation Analysis]
26 Campos A, Sharma S, Obermair A, Salomon C. Extracellular Vesicle-Associated miRNAs and Chemoresistance: A Systematic Review. Cancers (Basel) 2021;13:4608. [PMID: 34572835 DOI: 10.3390/cancers13184608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 Torki Z, Ghavi D, Hashemi S, Rahmati Y, Rahmanpour D, Pornour M, Alivand MR. The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update. Cancer Chemother Pharmacol 2021;88:771-93. [PMID: 34510251 DOI: 10.1007/s00280-021-04337-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Pan S, Wang Q, Zhang Q, Zhou M, Li L, Zhou X. A novel circular RNA, circPUS7 promotes cadmium-induced transformation of human bronchial epithelial cells by regulating Kirsten rat sarcoma viral oncogene homolog expression via sponging miR-770. Metallomics 2021;13:mfab043. [PMID: 34232319 DOI: 10.1093/mtomcs/mfab043] [Reference Citation Analysis]
29 Zheng H, Siddharth S, Parida S, Wu X, Sharma D. Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation. Cancers (Basel) 2021;13:3357. [PMID: 34283088 DOI: 10.3390/cancers13133357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
30 Cao J, Zhang M, Wang B, Zhang L, Fang M, Zhou F. Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies. Front Oncol 2021;11:658552. [PMID: 34277408 DOI: 10.3389/fonc.2021.658552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
31 Cumova A, Vymetalkova V, Opattova A, Bouskova V, Pardini B, Kopeckova K, Kozevnikovova R, Lickova K, Ambrus M, Vodickova L, Naccarati A, Soucek P, Vodicka P. Genetic variations in 3´UTRs of SMUG1 and NEIL2 genes modulate breast cancer risk, survival and therapy response. Mutagenesis 2021:geab017. [PMID: 34097065 DOI: 10.1093/mutage/geab017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Tan Y, Luo X, Lv W, Hu W, Zhao C, Xiong M, Yi Y, Wang D, Wang Y, Wang H, Wu Y, Zhang Q. Tumor-derived exosomal components: the multifaceted roles and mechanisms in breast cancer metastasis. Cell Death Dis 2021;12:547. [PMID: 34039961 DOI: 10.1038/s41419-021-03825-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
33 Wang M, Wei J, Ji T, Zang K. miRNA-770-5p expression is upregulated in patients with type 2 diabetes and miRNA-770-5p knockdown protects pancreatic β-cell function via targeting BAG5 expression. Exp Ther Med 2021;22:664. [PMID: 33986829 DOI: 10.3892/etm.2021.10096] [Reference Citation Analysis]
34 Zangouei AS, Alimardani M, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int 2021;21:213. [PMID: 33858435 DOI: 10.1186/s12935-021-01873-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
35 Taheri M, Mahmud Hussen B, Tondro Anamag F, Shoorei H, Dinger ME, Ghafouri-Fard S. The role of miRNAs and lncRNAs in conferring resistance to doxorubicin. J Drug Target 2021;:1-21. [PMID: 33788650 DOI: 10.1080/1061186X.2021.1909052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Tian C, Yang Y, Bai B, Wang S, Liu M, Sun RC, Yu T, Chu XM. Potential of exosomes as diagnostic biomarkers and therapeutic carriers for doxorubicin-induced cardiotoxicity. Int J Biol Sci 2021;17:1328-38. [PMID: 33867849 DOI: 10.7150/ijbs.58786] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 24.0] [Reference Citation Analysis]
37 Raue R, Frank AC, Syed SN, Brüne B. Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment. Int J Mol Sci 2021;22:2210. [PMID: 33672261 DOI: 10.3390/ijms22042210] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
38 Lakshmi S, Hughes TA, Priya S. Exosomes and exosomal RNAs in breast cancer: A status update. European Journal of Cancer 2021;144:252-68. [DOI: 10.1016/j.ejca.2020.11.033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 26.0] [Reference Citation Analysis]
39 Petrović N, Nakashidze I, Nedeljković M. Breast Cancer Response to Therapy: Can microRNAs Lead the Way? J Mammary Gland Biol Neoplasia 2021;26:157-78. [PMID: 33479880 DOI: 10.1007/s10911-021-09478-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
40 Li Z, Zhao S, Zhu S, Fan Y. MicroRNA-153-5p promotes the proliferation and metastasis of renal cell carcinoma via direct targeting of AGO1. Cell Death Dis 2021;12:33. [PMID: 33414440 DOI: 10.1038/s41419-020-03306-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
41 Li S, Yi M, Dong B, Jiao Y, Luo S, Wu K. The roles of exosomes in cancer drug resistance and its therapeutic application. Clin Transl Med 2020;10:e257. [PMID: 33377643 DOI: 10.1002/ctm2.257] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
42 Jia B, Zhang S, Wu S, Zhu Q, Li W. MiR-770 promotes oral squamous cell carcinoma migration and invasion by regulating the Sirt7/Smad4 pathway. IUBMB Life 2021;73:264-72. [PMID: 33326690 DOI: 10.1002/iub.2426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
43 Sabit H, Cevik E, Tombuloglu H, Abdel-Ghany S, Tombuloglu G, Esteller M. Triple negative breast cancer in the era of miRNA. Crit Rev Oncol Hematol 2021;157:103196. [PMID: 33307198 DOI: 10.1016/j.critrevonc.2020.103196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
44 Gan L, Yang H, Xiong Z, Yang Z, Wang T, Lyu G. miR-518a-3p Suppresses Triple-Negative Breast Cancer Invasion and Migration Through Regulation of TMEM2. Technol Cancer Res Treat 2020;19:1533033820977523. [PMID: 33251982 DOI: 10.1177/1533033820977523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Dobre EG, Dinescu S, Costache M. Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer. Cancers (Basel) 2020;12:E2698. [PMID: 32967267 DOI: 10.3390/cancers12092698] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
46 Mughees M, Kumar K, Wajid S. Exosome vesicle as a nano-therapeutic carrier for breast cancer. J Drug Target 2021;29:121-30. [PMID: 32787592 DOI: 10.1080/1061186X.2020.1808001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
47 Zhu M, Yang L, Wang X. NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis. Cancer Manag Res 2020;12:7277-89. [PMID: 32884343 DOI: 10.2147/CMAR.S257311] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
48 Wong JS, Cheah YK. Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer. Noncoding RNA 2020;6:E29. [PMID: 32668603 DOI: 10.3390/ncrna6030029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
49 Wong GL, Abu Jalboush S, Lo HW. Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis. Cancers (Basel) 2020;12:E1827. [PMID: 32646059 DOI: 10.3390/cancers12071827] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
50 Ozawa PMM, Jucoski TS, Vieira E, Carvalho TM, Malheiros D, Ribeiro EMSF. Liquid biopsy for breast cancer using extracellular vesicles and cell-free microRNAs as biomarkers. Transl Res 2020;223:40-60. [PMID: 32413499 DOI: 10.1016/j.trsl.2020.04.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
51 Wang Y, Wu N, Zhang J, Wang H, Men X. MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest. Onco Targets Ther 2020;13:4089-97. [PMID: 32494162 DOI: 10.2147/OTT.S241640] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
52 Liang Y, Song X, Li Y, Chen B, Zhao W, Wang L, Zhang H, Liu Y, Han D, Zhang N, Ma T, Wang Y, Ye F, Luo D, Li X, Yang Q. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. Mol Cancer 2020;19:85. [PMID: 32384893 DOI: 10.1186/s12943-020-01206-5] [Cited by in Crossref: 167] [Cited by in F6Publishing: 191] [Article Influence: 83.5] [Reference Citation Analysis]
53 Santana-Krímskaya SE, Franco-Molina MA, Zárate-Triviño DG, Prado-García H, Zapata-Benavides P, Torres-Del-Muro F, Rodríguez-Padilla C. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model. Biomed Pharmacother 2020;126:110062. [PMID: 32172064 DOI: 10.1016/j.biopha.2020.110062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
54 Goh CY, Wyse C, Ho M, O'beirne E, Howard J, Lindsay S, Kelly P, Higgins M, Mccann A. Exosomes in triple negative breast cancer: Garbage disposals or Trojan horses? Cancer Letters 2020;473:90-7. [DOI: 10.1016/j.canlet.2019.12.046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
55 Kanchan RK, Siddiqui JA, Mahapatra S, Batra SK, Nasser MW. microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy. Mol Cancer 2020;19:29. [PMID: 32059676 DOI: 10.1186/s12943-020-1140-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
56 Deepak KGK, Vempati R, Nagaraju GP, Dasari VR, S N, Rao DN, Malla RR. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683. [PMID: 32050092 DOI: 10.1016/j.phrs.2020.104683] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 47.5] [Reference Citation Analysis]
57 Denisov EV, Jolly MK, Shubin VP, Tsukanov AS, Cherdyntseva NV. Critical Steps in Epithelial-Mesenchymal Transition as Target for Cancer Treatment. Approaching Complex Diseases 2020. [DOI: 10.1007/978-3-030-32857-3_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W, Yu M, Lin J, Cui Q. MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer. Cells 2019;8:E1492. [PMID: 31766744 DOI: 10.3390/cells8121492] [Cited by in Crossref: 70] [Cited by in F6Publishing: 79] [Article Influence: 23.3] [Reference Citation Analysis]
59 Jinesh GG, Brohl AS. The genetic script of metastasis. Biol Rev Camb Philos Soc 2019. [PMID: 31663259 DOI: 10.1111/brv.12562] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
60 Jiang Q, Yuan Y, Gong Y, Luo X, Su X, Hu X, Zhu W. Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo. J Cancer Res Clin Oncol 2019;145:2951-67. [PMID: 31654121 DOI: 10.1007/s00432-019-03051-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
61 Jia L, Song Y, Mu L, Li Q, Tang J, Yang Z, Meng W. Long noncoding RNA TPT1‐AS1 downregulates the microRNA‐770‐5p expression to inhibit glioma cell autophagy and promote proliferation through STMN1 upregulation. J Cell Physiol 2020;235:3679-89. [DOI: 10.1002/jcp.29262] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
62 Rahman MM, Brane AC, Tollefsbol TO. MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer. Cells 2019;8:E1214. [PMID: 31597272 DOI: 10.3390/cells8101214] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 16.3] [Reference Citation Analysis]
63 Wang G, Zhao W, Wang H, Qiu G, Jiang Z, Wei G, Li X. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2. Med Sci Monit 2019;25:7209-17. [PMID: 31553714 DOI: 10.12659/MSM.919219] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
64 Zhao W, Li H, Yang S, Guo D, Chen J, Miao S, Xin Y, Liang M. MicroRNA-152 suppresses cisplatin resistance in A549 cells. Oncol Lett 2019;18:4613-20. [PMID: 31611969 DOI: 10.3892/ol.2019.10834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
65 Patras L, Banciu M. Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression. CPD 2019;25:1980-2006. [DOI: 10.2174/1381612825666190701143845] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
66 Liu Q, Peng F, Chen J. The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer. Int J Mol Sci. 2019;20. [PMID: 31395836 DOI: 10.3390/ijms20163884] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
67 Zheng P, Dong L, Zhang B, Dai J, Zhang Y, Wang Y, Qin S. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19. Histochem Cell Biol 2019;152:281-91. [DOI: 10.1007/s00418-019-01794-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
68 Groza M, Zimta AA, Irimie A, Achimas-Cadariu P, Cenariu D, Stanta G, Berindan-Neagoe I. Recent advancements in the study of breast cancer exosomes as mediators of intratumoral communication. J Cell Physiol 2020;235:691-705. [PMID: 31328284 DOI: 10.1002/jcp.29096] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
69 Najminejad H, Kalantar SM, Abdollahpour‐alitappeh M, Karimi MH, Seifalian AM, Gholipourmalekabadi M, Sheikhha MH. Emerging roles of exosomal miRNAs in breast cancer drug resistance. IUBMB Life 2019;71:1672-84. [DOI: 10.1002/iub.2116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
70 Tsai HY, Fu SL, Tseng LM, Chiu JH, Lin CH. hnRNPK S379 phosphorylation participates in migration regulation of triple negative MDA-MB-231 cells. Sci Rep 2019;9:7611. [PMID: 31110205 DOI: 10.1038/s41598-019-44063-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
71 Sang Y, Chen B, Song X, Li Y, Liang Y, Han D, Zhang N, Zhang H, Liu Y, Chen T, Li C, Wang L, Zhao W, Yang Q. circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. Mol Ther 2019;27:1638-52. [PMID: 31153828 DOI: 10.1016/j.ymthe.2019.05.011] [Cited by in Crossref: 189] [Cited by in F6Publishing: 206] [Article Influence: 63.0] [Reference Citation Analysis]
72 Noyan S, Gurdal H, Gur Dedeoglu B. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells. PLoS One 2019;14:e0215894. [PMID: 31009516 DOI: 10.1371/journal.pone.0215894] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
73 Abdel-Mohsen MA, Abdel Malak CA, El-Shafey ES. Influence of copper (I) nicotinate complex and autophagy modulation on doxorubicin-induced cytotoxicity in HCC1806 breast cancer cells. Adv Med Sci 2019;64:202-9. [PMID: 30798072 DOI: 10.1016/j.advms.2018.08.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
74 Anestis A, Sarantis P, Theocharis S, Zoi I, Tryfonopoulos D, Korogiannos A, Koumarianou A, Xingi E, Thomaidou D, Kontos M, Papavassiliou AG, Karamouzis MV. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer. J Cancer Res Clin Oncol 2019;145:1221-33. [PMID: 30805773 DOI: 10.1007/s00432-019-02872-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
75 Zhu L, Chen Y, Nie K, Xiao Y, Yu H. MiR-101 inhibits cell proliferation and invasion of pancreatic cancer through targeting STMN1. Cancer Biomark 2018;23:301-9. [PMID: 30198871 DOI: 10.3233/CBM-181675] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
76 Liu SS, Maguire EM, Bai YS, Huang L, Liu Y, Xu L, Fauzi I, Zhang SQ, Xiao Q, Ma NF. A Novel Regulatory Axis, CHD1L-MicroRNA 486-Matrix Metalloproteinase 2, Controls Spermatogonial Stem Cell Properties. Mol Cell Biol 2019;39:e00357-18. [PMID: 30455250 DOI: 10.1128/MCB.00357-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
77 Yin Z, Ren W. MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin. Onco Targets Ther 2019;12:759-71. [PMID: 30774364 DOI: 10.2147/OTT.S176618] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
78 Zhang JF, Zhang JS, Zhao ZH, Yang PB, Ji SF, Li N, Shi QD, Tan J, Xu X, Xu CB, Zhao LY. MicroRNA-770 affects proliferation and cell cycle transition by directly targeting CDK8 in glioma. Cancer Cell Int 2018;18:195. [PMID: 30524203 DOI: 10.1186/s12935-018-0694-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
79 Rui X, Wang L, Pan H, Gu T, Shao S, Leng J. LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis. J Cell Mol Med 2019;23:865-76. [PMID: 30394665 DOI: 10.1111/jcmm.13986] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
80 Han J, Han B, Wu X, Hao J, Dong X, Shen Q, Pang H. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicology and Applied Pharmacology 2018;359:55-61. [DOI: 10.1016/j.taap.2018.09.018] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 13.0] [Reference Citation Analysis]
81 Kong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, Liu Y, Zhang N, Yang Q. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 2018;. [PMID: 30362551 DOI: 10.1002/jcp.27587] [Cited by in Crossref: 93] [Cited by in F6Publishing: 106] [Article Influence: 23.3] [Reference Citation Analysis]
82 Liu J, Jia Y, Jia L, Li T, Yang L, Zhang G. MicroRNA 615-3p Inhibits the Tumor Growth and Metastasis of NSCLC via Inhibiting IGF2. Oncol Res 2019;27:269-79. [PMID: 29562959 DOI: 10.3727/096504018X15215019227688] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]